BBI-001

BBI-001 is a first-in-class, non-absorbed oral small molecule therapy in development for the treatment of iron overload, particularly hereditary hemochromatosis. It acts as an iron chelator, rapidly forming a strong and selective iron chelate in the digestive tract to inhibit dietary iron absorption. The drug is designed to remain restricted to the gastrointestinal tract, thereby maximizing safety by minimizing systemic exposure. In Phase 1a/b clinical trials, BBI-001 was well tolerated with no dose-limiting toxicities and demonstrated a statistically significant reduction in dietary iron absorption after single-dose administration. The developer is Bond Biosciences, which focuses on non-absorbed oral therapies that bind excess ions locally in the GI tract[1][2][3][4][5][6][7].